Record entry and a shortlist oozing quality for Business Weekly Awards
Judges face a tough job selecting winners from a record entry and high quality shortlist for the 2023 Business Weekly Awards. Lead sponsor Mills & Reeve will continue interviewing and preparing confidential reports on selected businesses over the next couple of months and no winners will be unveiled before the night of the Awards banquet at Homerton College, Cambridge, on Thursday September 14.
Nobel Prizewinning scientist Sir Greg Winter, the guest speaker, will be running the rule over Cambridge’s track record for producing game-changing science & technology over the years.
Bleeding edge innovation again abounds in the shortlist which represents a quality in depth across all 14 Award categories:
- Young Company of the Year
- Cambridge Judge Graduate Business of the Year
- The Sir Michael Marshall Engineering Excellence Award
- Disruptive Technology
- The Pathfinder Award
- Technology Scale-up
- Life Science Scale-up
- Life Science Innovation
- International Trade Champion
- Quoted Company of the Year.
- Cambridge Judge Business School Woman Entrepreneur of the Year
- Sustainability Champion
- DeepTech Innovation
- Investment of the Year
As well as the category winners, judges will choose a Business of the Year – a coveted title won last year by Bicycle Therapeutics.
SHORTLISTED COMPANIES
Advanced Infrastructure
Founded in 2020, Advanced Infrastructure has developed an innovative Local Area Energy Planning Tool (LAEP+) which has been deployed across five local authorities and a Distribution System Operator. Through its innovative GIS tools, datasets and APIs Advanced Infrastructure makes it easier for local authorities, distribution network operators and consultants to plan local energy transitions and operate using low carbon power.
Astex Pharmaceuticals
In the last 20 years, Astex has grown from a start up, pioneering its innovative Pyramid fragment-based drug discovery platform to find new drugs for cancer and more latterly neurodegenerative diseases. The platform has led to the discovery of two cancer drugs that are on the market (via Novartis and J&J), and during 2022 a third successfully completed Phase 3 trials (via AstraZeneca) and is expected to reach the market in 2023, subject to regulators approval.
Audiotelligence
AudioTelligence has developed Orsana™, the first universal assistive listening device designed for hearing clearly in noise – with or without hearing aids. This radical new solution will leverage the new Bluetooth Low Energy, low latency codec, which will allow the device to connect wirelessly to BLE enabled hearing aids or to wireless earbuds, with the low latency necessary for face-to-face conversations. For the first time, consumers will be able to add additional hearing enhancement to any brand of Bluetooth Low Energy enabled hearing aids, or simply enhance their ability to hear in noise by connecting wirelessly to earbuds.
Bicycle Therapeutics
Bicycle is pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesised medicines. Bicycles represent a unique therapeutic class, combining the pharmacological properties associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed. Bicycle’s collaborations with leading organisations that have deep therapeutic expertise outside of oncology leverage the ability of Bicycles to address a wide variety of targets and provide further validation of the potential of its approach.
Biofidelity
Biofidelity is dedicated to unleashing the potential of genomics to transform human health. The company’s adaptive platform technology removes the noise from genomic data, providing only the information needed to make decision-making less complex, faster, and more efficient. The company is driving global decentralisation of precision oncology – solving key issues in Next-Generation Sequencing, and, ultimately, transforming millions of lives globally through access to the vital information needed for accurate targeting and monitoring of cancer treatment.
BIOS Health
BIOS is unlocking the potential of the nervous system. Taking place in eight clinics across the globe over three years, a new NIH REVEAL programme will be the largest ever single clinical study of human neural data. As core partner, BIOS Health is providing the software infrastructure for the project, and will be instrumental to its success. This is a major validation of BIOS’ platform, and allows the technology to become the foundation for the next wave of precision neural medicines to treat chronic disease, through the development of a new class of treatments – neural digital therapies.
Cambridge Mechatronics Ltd
In the past year, CML has developed a new product range designed to elevate smartphone camera actuator performance beyond the capability of the incumbent market leader. Using 8 SMA wires, the company has created an all-in-one AF+OIS actuator which has been licenced to four international manufacturers, attracted by the simple design and low-cost potential. To date, >5M units have shipped, winning top camera marks in the DxOMark charts.
Cellular Origins
Cellular Origins was spun-out of TTP to transform patient access to cell and gene therapies by addressing the current challenges associated with scalable, cost-effective and efficient manufacture. It works collaboratively with a growing list of partners to enable scale-up of therapy manufacturing, without process redevelopment, to ensure that we can deliver these life saving therapies to patients.
Cemfree, part of Db Group
Cemfree has emerged as a pioneering leader in the journey to net zero, showcasing the potential to dramatically reduce carbon footprints in the built environment through sustainable operations. Cemfree has developed an ultra-low carbon alternative to traditional Portland cement (PC), which can offer dramatic carbon emission savings of up to 85 per cent. It claims that its innovative science and technology paves the way for a greener future in construction, offering a viable solution that significantly minimises environmental impact.
Clinked.com
Clinked is a rapidly expanding SaaS company focused on delivering top-tier client and document management solutions to businesses worldwide with utmost security. Its success is driven by a strong and growing customer base, which includes a sizeable portion of clients from the UK & US, as well as an increasing number from the EU and beyond. Clinked is a trusted supplier of UK Government services. Its technology platform has gained significant popularity across a range of industries, including financial, legal, accounting, insurance, property, education, engineering, manufacturing and marketing.
CN Bio
Despite activity towards reducing animal model use in drug development, including groundbreaking legislature from the FDA and Canadian Government, researchers are hesitant to adopt organ-on-a-chip due to cost, scalability and data reliability concerns. Enter, CN-Bio’s PhysioMimix™ Higher-Throughput (HT) System. Alongside the new Liver-48 plate, it allows 144 assays to be conducted simultaneously, reducing costs/sample, whilst increasing data robustness and reproducibility. The system enables the benefits of the company’s well-validated human liver model to be realised earlier in discovery. Studies investigating drug efficacy, disposition or safety deliver insights that refine in vivo experimental design and reduce the number of animals required.
Decorte Future Industries
DFI deploys novel Machine Learning methods, inspired by research at the University of Cambridge, to extract health data directly from sound collected by standard microphones. The company previously built various hardware architectures to support its data collection efforts. Its core product is an AI engine that any third party can connect to in order to extract complex and accurate human health data simply from microphones embedded in existing devices and infrastructure. DFI non-invasively extracts cardiovascular, respiratory, mental, neurological and gastrointestinal health data from individuals’ bodies at a fraction of the cost and complexity of existing methods.
DeepMirror
AI will empower the Life Sciences and is seemingly available to everyone – but availability is not accessibility, says Cambridge startup DeepMirror. Most companies fail to harness AI/ML due to high upfront costs and insufficient understanding on where ML/AI adds value. DeepMirror claims to solve this by building intuitive AI-powered software that learns from laboratory results to suggest the next experiment and is useable by everyone, thus guiding researchers in the development of novel therapies and bio-innovations.
Domainex
Domainex revenues increased by 19 per cent in 2022, following a 24 per cent increase in 2021. The company increased head count by 33 (38 per cent) in the last 12 months and is still recruiting. It has established several new techniques, such as flow cytometry and ‘Jess’: Simple Western™ Blotting, providing clients with a greater range of services. Domainex has also invested in a significant amount in new equipment (~£2 million in 2022). Earlier this year the company won a King’s Award for Enterprise: International Trade 2023.
Eagle Genomics
Eagle Genomics is a pioneering TechBio platform scale-up at the intersection of biology, data sciences and bioinformatics. Its award-winning AI-augmented knowledge discovery platform, the e[datascientist], enables scientists to exploit complex microbiome data, digitising R & D and accelerating product development. It has strong commercial traction with Fortune 500 enterprises across several industries including Agriculture, Food Production Systems, Nutrition, Beauty & Personal Care, and Biopharma. The e[datascientist] enables the delivery of innovative, sustainability-driven solutions, improving impact in climate resilience, plant nutrient density, and data-driven wellness and human health.
Enhanc3D Genomics Ltd
Enhanc3D Genomics is developing a disruptive technology capable of unlocking the 3D spatial genome for target and biomarker discovery. In 2022, the company closed a £10 million Series A round, led by BGF and Parkwalk Advisors and appointed Dr Chris Torrance, founder and Chairman of Phoremost and founder of Horizon Discovery, as Non-Executive Chair. The company also received grant funding, one-year residency at Johnson & Johnson Innovation – JLABS, and mentorship from experts at J&J’s Family of Companies. The company recently expanded to a new 5,000 sq ft facility at St John’s Innovation Park.
Evonetix
Evonetix is developing a radically different approach to gene synthesis – a highly parallel desktop platform for long DNA synthesis at unprecedented accuracy and scale. Placing gene synthesis in the hands of researchers will alleviate the primary bottleneck to scaling up engineering biology, unlocking potential across pharma, biotech, and agriculture. In February Evonetix closed an oversubscribed £20m financing round, extending its total series B funding to over £44m. And in May it delivered its first chip-synthesized DNA to the University of Cambridge.
Featurespace
Featurespace was named as one of the winners of an inaugural transatlantic crime-busting competition at President Biden’s second Summit for Democracy. The company emerged victorious in the International PETs challenge launched by the UK and US governments to promote privacy-enhancing technology solutions and help create a world where financial crime doesn’t pay. Featurespace is continually developing market-leading solutions to fight online financial fraud with the use of real-time machine learning software powered by its innovative Adaptive Behavioral Analytics and Automated Deep Behavioural Networks. The company’s ARIC™ Risk Hub is today deployed in some of the world’s largest banks, payments processors and merchant acquirers.
FlexEnable
FlexEnable has developed and patented a complete manufacturing solution for flexible Liquid Crystal (LC) Cells on bioplastic films instead of glass to make the world’s thinnest and biaxially formable active optical films. This breakthough in flexible, lightweight LC optics has major role to play in AR/VR optics as well as vision correction. It also enables tintable automotive smart windows (sunroofs) and lightweight switchable ePrivacy screens for notebooks. Within two years of developing this unique LC cell technology, derived from its flexible display development, FlexEnable has grown this into a significant business area, with active commercial projects already in seven figures. Current clients for the company’s flexible LC cells are some of the biggest brands in the world.
Forefront RF
Forefront RF makes front-ends with a tunable RF filter, based on its Adaptive Passive Cancellation technology. APC is a revolutionary RF development that integrates all mobile low-band frequencies into a single small module. It solves the current complexity of size and cost issues for modern phones. Due to the global band coverage, supply chain inefficiencies and e-waste are strongly reduced. Forefront RF will be positioned as a major and sustainable growing business, delivering strong returns for the UK. It will bolster RF know-how and forms an opportunity to build the high tech ecosystem and engineering talent pool around broader Cambridge.
GetBusy plc
With over 20 years’ proven success providing powerful document management software for professional and financial service firms across the UK, US and Australia, GetBusy recently launched next-generation document handling capabilities into the global cloud ERP market with its brand new Workiro product. Recognition was swift to follow, winning Oracle’s coveted SuiteCloud International Partner of the Year and GetBusy has subsequently been signing up distribution partners at pace. Reporting 25 per cent revenue growth from its core document products in 2022, GetBusy’s market opportunity is significantly broadened through the launch of Workiro, providing opportunity for sustained strong growth for years to come.
Immaterial Ltd
Immaterial is a cleantech company co-founded by Professor David Fairen-Jimenez from the University of Cambridge. Its disruptive technology allows the company to custom-design and manufacture advanced materials that offer the most efficient and lowest-cost carbon capture and hydrogen storage solutions. Over the last year, Immaterial has scaled up its production from grams to kg/day-scale, adapted all the syntheses to be environmentally friendly, engineered game-changing ways of harnessing the performance of their materials, built a strong pipeline of customers and expanded to welcome 11 new joiners. The now 22-employee-strong company has also successfully retained eight Cambridge graduate talents.
InferSens
InferSens’ edge AI sensor technology delivers machine learning on-device, enabling accurate, real-time monitoring in areas previously hard or impossible to address. Its first product, a non-invasive flow and temperature sensor, automates many of the manual aspects of Legionella risk monitoring in building water systems. InferSens developed its technology with edge AI in mind. When ultra-efficient, next-generation processors became available, InferSens applied its deep learning models and innovative mechanical and systems engineering to break the logjam of power consumption vs performance. Leading the way with its revolutionary technology, InferSens has identified significant potential in low power, rich data and smart sensing applications.
Intellegens
A spin-out from Cambridge’s Cavendish Laboratory, Intellegens provides innovative machine learning that is used in research-intensive applications to extract value from real-world experimental and process data. Benefits include better, greener products and processes, and substantial reductions in the amount of experiment needed to achieve research objectives, speeding time-to-market. A growing customer-base is reflected in recent webinars with applications to food formulation (at Yili), additive manufacturing (Lawrence Livermore National Laboratory), clean air applications (Johnson Matthey), and biopharmaceuticals (CPI). The company has also grown its team to around 30 people and moved into a new HQ.
Iprova
Iprova has developed ML and NLP based technologies which augment and enhance the human ability to invent. This enables the generation of commercially relevant, breakthrough inventions in real-time in direct response to day-to-day changes around the world. Iprova’s technology enables the creation of inventions by identifying and connecting useful inventive signals from day-day social, market and technological advances –even if they are very distant to the target invention area. The technology has been built on Iprova’s 10 years of research into invention creation, which captures our experience of working with leading technology companies to create over 2,500 inventions.
Luminance
Luminance has been transforming the law since 2016. With an LLM that has been informed by 150+ million verified legal documents, Luminance is automating the way businesses draft, negotiate, and process contracts. This year, Luminance launched its AI chabot, Ask Lumi, a pioneering development which enables users to ask questions about any contract and receive instant responses and redraft clauses at the click of a button.
Macomics
Since its expansion into Cambridge, alongside its Edinburgh base Macomics has continued to expand and progress its proprietary macrophage based drug discovery platform. Macrophage are one of the most common immune cells, but are complex and their potential for precision immune-oncology drugs is just entering a golden area. In Q1 2023 Macomics closed a significant deal and its founders published in Nature Cancer Reviews a major review on the history and potential of macrophage biology, underlining the company’s leadership understanding.
Maxion Therapeutics
Maxion develops biologic medicines for hard-to-treat diseases driven by ion channel proteins. Its KnotBody® platform overcomes current challenges, combining millions of years of knottin (natural ion channel modulators) evolution with state-of-the-art antibody technologies. Maxion recently secured a £13m Series A round and £2m Innovate UK funding. In the last three months its team grew from 8 to 21. Maxion’s team, with a strong track record, includes CEO Dr John McCafferty (CAT, IONTAS) and CSO Dr Aneesh Karatt Vellatt (IONTAS). McCafferty co-invented antibody phage display technology – the basis of globally best-selling drug, Humira, and Sir Greg Winter’s 2018 Nobel Prize.
Monumo
AI is the future of engineering, enabling system-level optimisation of complex machines. Monumo is at the forefront of this new technology trend, doing for electric motors what AI has done for drug discovery and genetics. Electric motors and generators are essential to tackling the climate crisis. The better they are the quicker we will achieve global sustainability. Electrification of every sector demands smaller, lighter, cooler, cheaper, more sustainable and more efficient motors. For the first time ever Monumo’s technology will explore the full motor design space to create the motors that will drive the 21st Century.
NRG Therapeutics
NRG Therapeutics is leveraging breakthrough science in the field of mitochondrial biology to identify new therapeutic targets to treat neurodegenerative disorders. It is developing novel, drug-like ‘second generation’ mitochondrial permeability transition pore (mPTP) inhibitors and has discovered the first orally bioavailable and brain-penetrant mPTP inhibitors. These inhibitors prevent the pathological effects of misfolded TDP-43 and α-synuclein, two toxic proteins that cause the degeneration of motor neurones and dopaminergic neurones in ALS and Parkinson’s respectively.
Nuclera
Nuclera’s mission is to revolutionise human health by making it quick and convenient to obtain high-quality, soluble, and active proteins. In the past 12 months Nuclera’s team of over 100 employees based in Cambridge, UK, and Boston, MA, have reached significant milestones, including working with leading pharmaceutical companies, moving from $58 million in series B funding to series C funding, relocating to state-of-the art facilities, all putting Nuclera many steps closer to shaping the next generation of life science technologies. With the ground-breaking eProtein Discovery™ system, scientists can automate protein construct screening, providing crucial information to scale up protein production off-platform in less than 48 hour – accelerating drug discovery pipelines, facilitating unprecedented scientific progress.
Opto Biosystems
Opto is a new company based in Cambridge, founded and managed by two PhD engineering graduates from the University of Cambridge. It is developing minimally-invasive neurological technologies. The founders believe these technologies will become a prominent feature of modern medicine, enabling advances in brain cancer, epilepsy and neurodegenerative disease treatment. Opto has had recent success in fundraising and attaining clinical partners and is now focused on building its Cambridge-based team and trailing its groundbreaking technology with its partners in the UK and around the world.
Paragraf
Paragraf has unlocked the next electronics era with the first mass-produced, graphene-based devices, delivering step changes in performance and power reduction. In five years, the company has developed its process, built and shipped product, and started generating revenues. Private investment totalling £67 million has grown the company to 125 employees across R & D and new manufacturing UK facilities, and recently acquired California-based Cardea Bio, boosting global leadership. Paragraf has worldwide partners and customers building its devices into applications including electric vehicles, renewable energy, quantum computing and medical diagnostics, utilising the performance and energy efficiency of graphene enabled by a unique, proprietary manufacturing process.
PervasID
As founder and CEO, Sabesan Sithamparanathan successfully grew PervasID, a Cambridge University spin-out company, from its inception to a multimillion-dollar global enterprise, raising over $10 million in funding, and in the process providing transformative solutions to healthcare, industrial, retail and supply chain sectors with a complete product suite of the world’s most accurate RFID readers. Recently PervasID signed a £22.5m deal with the second largest inventory solution provider in retail. PervasID is rolling out the solution to several retailers including H&M, NHS and Stanley.
PhoreMost
PhoreMost is a disrupter in the pharmaceutical industry, with a mission to accelerate, diversify and rationalise drug discovery. Driving the discovery of tomorrow’s medicines, PhoreMost is advancing a pipeline of first-in-class targets in oncology and targeted protein degradation (TPD). PhoreMost, powered by its SITESEEKER® platform, is addressing some of the biggest challenges in TPD, one of the most exciting fields within the biopharma industry, to advance next-generation degrader therapeutics. PhoreMost has a pipeline of collaborations with industry leaders to progress its mission and identify novel druggable targets, such as Roche, Boehringer Ingelheim, and Otsuka.
Porotech
In May 2023, Porotech unveiled the world’s first monolithic full-colour microdisplay, powered by our proprietary DynamicPixelTuning® (DPT®) technology. DPT is the world’s first “all-in-one” microLED, eliminating the need for RGB sub-pixels, further colour conversion/filtering, and complex stacking architectures, all whilst enabling colour uniformity and simplified system design to deliver high-performance microLED displays and optical solutions. This is a significant milestone for both the company and the microLED industry, as DPT pixels open the market for additional display applications using microLEDs beyond AR/VR, including smart watches, smart phones, tablet.
Qkine
Qkine is a rapidly scaling specialist manufacturer of bioactive proteins for the life science market. Spun out from Cambridge University, Qkine actively recruits local Cambridge graduates and supports local initiatives such as Cambridge Unlocked to inspire young people into STEM careers. Qkine doubled its headcount in the last financial year to strengthen R & D and increase the product pipeline, increase manufacturing, and commercial teams. Along with a 175 per cent increase in overall revenue, Qkine had a 200 per cent increase in export revenue, exporting to 30 countries.
Revvity Inc.
Revvity, a visionary partner in developing technologies and solutions to help solve the world’s greatest health challenges, launched several solutions to power discovery to cure: EnVision Nexus to speed discovery workflows; Signals Research Suite for improved drug development workflows; and the UNIQO 160 from EUROIMMUN for cutting-edge autoimmune disease diagnostics. Revvity also signed a licensing agreement with AstraZeneca for use of its next-generation Pin-Point™ base editing system to advance cell therapy programs. Establishing the Centre of Excellence for Genomic Insight at Cambridge Research Park further demonstrates Revvity is living its purpose to expand the boundaries of human potential through science.
Riverlane
Riverlane is becoming one of the most successful deep technology companies to ‘spin out’ from Cambridge university and is now one of the most important quantum computing companies in the world. Quantum computers can transform humanity by designing solutions to currently unsolvable challenges in fields like clean energy and drug design. Riverlane is building the operating system that makes them work. Founded by Steve Brierley in 2016, Riverlane has 100+ employees in Cambridge, Boston, San Francisco and Munich; partners the majority of the world’s leading quantum computing companies; and is the biggest recipient of UK Government grants and contracts.
RoboK
RoboK uses AI to transform existing CCTV cameras into proactive analytics engines. Highlights of its achievements in last 12 months include:-
Funding & customers – Customers incl. critical national infrastructure companies like Network Rail, the Bristol Port Company and National Highways and $2.1m in recent funding ($4m in total). Significant impact – One customer saw over 90 per cent reduction in safety breaches and invested in RoboK’s latest round. Customers choose RoboK solutions to understand why hazards exist and to create safer & better environment for their workforce. Leadership: Led by female co-founder and CEO, RoboK employs a diverse team of many nationalities.
sAInaptic
sAInaptic is developing an AI-based assessments model that brings feedback-driven teaching & learning to users at scale. Its technology is proprietary and evidence-based and leverages recent advances in AI to auto-mark descriptive answers and give instant, teacher-like feedback. This enables students to course correct, while reducing marking workload for teachers. Since its launch in Sept ‘22, sAInaptic has grown to over 14k registered users, with students from over 1,000 schools and 20 countries using the technology to learn more effectively. sAInaptic is led by two female co-founders, both Cambridge graduates, passionate about using AI to transform education.
Secondmind
Secondmind pushes the boundaries of AI to help automotive engineers design better cars faster with next-generation optimisation solutions that crush skyrocketing engineering complexity in vehicle design and development. The cloud-native Secondmind Optimization Engine, which is powered by Active Learning and underpinned by award-winning machine learning research, radically reduces error correction costs, design simulation time, and calibration overhead. By empowering engineers at car makers like Mazda to blend their automotive expertise with AI and intelligently automate experimental design processes, Secondmind delivers better results in a fraction of the time with 80 per cent less data, and accelerates the industry’s transition to electrification.
The SecOps Group
The SecOpps Group is a globally recognised IT security company with extensive experience of providing cyber security consultancy and education services. It believes that security is a continuous process, which has to progress with time and in accordance with the customer needs and constantly evolving threats. Its core business comprises of two units: Consultancy & Education.
Semarion
Semarion is a seed-stage technology company revolutionising drug discovery by combining material science and cell biology. Its innovation addresses key bottlenecks in adherent cell assay workflows, critical for evaluating drug targets and compounds. These cells require surface attachment, limiting throughput, reproducibility, and cost efficiency. Semarion’s solution – the SemaCyte® microcarrier platform – brings flexibility, miniaturisation and multiplexing to biopharma workflows, ensuring faster and superior data generation. With early adopter collaborations underway, it anticipates a commercial launch in 2024.
Sepura
Sepura is a telecoms equipment provider that develops and supplies radio terminals, accessories and software applications for business and mission critical communications. The company specialises in Terrestrial Trunked Radio and LTE technology. Its SCU3 is the first Sepura hybrid device for mission critical users, enabling dual use of TETRA and LTE connectivity for the first time, allowing data-intensive functions such as video streaming, mapping, dispatch and other applications alongside TETRA’s proven voice communications. This is achieved in a single product, built on 20 years’ experience supplying public safety organisations, allowing seamless user migration and minimising total devices required by organisations.This solution will widen the capability of users from a single mission critical device, with a future proofed solution to perform the functions currently managed on multiple devices.
Shearline Precision Engineering
The Shearline Group has been involved in the game-changing engineering and manufacturing of thousands of components and assemblies for half a century. The company is celebrating its 50th year in business. In the last 12 months alone, Shearline has supported customers, old and new, by manufacturing their precision parts, providing design for manufacture advice to offer cost savings. From the latest innovations in battery technology to maintaining the volume production of cutting-edge medical devices – Shearline remains passionate about providing precision engineering solutions to all industries, spanning a diverse range of end applications.
Sphere Fluidics
Harnessing patented picodroplet microfluidic technology, Sphere Fluidics’ instruments and consumables enable users to find, analyse and isolate the most valuable cells with ease and speed. The flagship product, Cyto-Mine®, is an automated platform capable of screening up to 40 million cells in a matter of hours – compared with 10,000 typically achieved using multi-step manual techniques. Its unrivalled throughput accelerates biopharmaceutical discovery and development, cell therapy, and synthetic biology workflows, easing the journey of discovery in labs globally. It is widely recognised by industry experts, demonstrating significant time and cost savings, and providing absolute assurance of quality and reliability.
Vector BioScience
Vector Bioscience is a University of Cambridge spin-out that investigates novel solutions for drug delivery. Thanks to its modular ‘plug-and-play’ materials, the company ensures targeted treatments with higher efficacies and fewer side effects, something especially important in cancer therapy. Vector has achieved promising in-vivo data and received sizeable non-dilutive funding to accelerate the growth and commercialisation of the technology. Vector has very ambitious plans for the next three years and so far, the preliminary data shows that it will be able to facilitate targeted cancer treatment with room temperature storage.
Zetta Genomics
Zetta Genomics unleashes the power of precision medicine. As growing understanding of the human genome unlocks personalised healthcare, Zetta’s XetaBase technology brings genomic data interpretation into the lab and clinic. The company was spun out of a University of Cambridge and Genomics England collaboration in 2022. It has secured £2.5m in global investor seed funding; attracted outstanding talent and is driving partnerships with health innovators, including Fujitsu, Microsoft and the NHS.
